In patients with type 2 diabetes using basal insulin, more pramlintide recipients achieved the composite diabetes control endpoint than placebo recipients.
In plain wordsIn patients with type 2 diabetes using basal insulin, the combined diabetes control target was reached more often with pramlintide than placebo.
- Peptide
- Pramlintide (Symlin)
- Outcome
- IncreaseComposite diabetes control endpoint
- Study
n = 212
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 60 or 120 microg b.i.d./t.i.d. · 16 weeksAs given in this study (human).
Measurements
- Composite endpoint achievement
- 25%
- pramlintide
- Composite endpoint achievement
- 7%
- placebo
Source sentences
More pramlintide- than placebo-treated patients achieved the composite end point (25 vs. 7%; P < 0.001).
4 context sentences(design, population, supporting numbers)
The other coprimary end point was a composite measure of overall diabetes control comprising A1C or = 0.5%, mean daily postprandial glucose (PPG) increments < or = 40 mg/dl, no increase in body weight, and no severe hypoglycemia.
Patients meeting all four conditions at week 16 achieved this end point.
In a 16-week, double-blind, placebo-controlled study, 212 patients using insulin glargine with or without oral antidiabetes agents (OAs) were randomized to addition of pramlintide (60 or 120 microg b.i.d./t.i.d.) or placebo.
Insulin glargine was adjusted to target a fasting plasma glucose concentration of 70-100 mg/dl.